Biosimilar push: Dr Reddy’s gets EU nod for denosumab copy; Prolia, Xgeva rivals set for rollout
Biosimilar push: Dr Reddy’s gets EU nod for denosumab copy; Prolia, Xgeva rivals set for rollout
Dr. Reddy's Laboratories has achieved a significant regulatory win with the European Commission approving AVT03, its biosimilar for osteoporosis treatment. This authorization extends across all EU nations, plus Iceland, Liechtenstein, and Norway. Developed and manufactured by Alvotech, AVT03 will be marketed by Dr. Reddy's in Europe and the US, offering a new option for bone health management.
Dr. Reddy's Laboratories has achieved a significant regulatory win with the European Commission approving AVT03, its biosimilar for osteoporosis treatment. This authorization extends across all EU nations, plus Iceland, Liechtenstein, and Norway. Developed and manufactured by Alvotech, AVT03 will be marketed by Dr. Reddy's in Europe and the US, offering a new option for bone health management.
Dr. Reddy's Laboratories has achieved a significant regulatory win with the European Commission approving AVT03, its biosimilar for osteoporosis treatment. This authorization extends across all EU nations, plus Iceland, Liechtenstein, and Norway. Developed and manufactured by Alvotech, AVT03 will be marketed by Dr. Reddy's in Europe and the US, offering a new option for bone health management. 
